One of the remaining issues is NAFLD patients with T2DM who failed to normalize serum ALT levels by SGLT2 inhibitors, herein defined as “refractory to SGLT2 inhibitor”. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.